Adverse reactions to Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species

Tuberculosis

Volumn 88, Issue 4, 2008, Pages 344-357

  Murphy, D ^a   Corner, L A L ^a   Gormley, E ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adverse reactions; BCG; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE;

ABSCESS; ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; CATTLE; DELAYED HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; EXPERIMENTAL ANIMAL; GUINEA PIG; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INJECTION SITE ABSCESS; KELOID; LYMPHADENITIS; LYMPHOCYTOSIS; MONKEY; MYCOBACTERIUM BOVIS; NONHUMAN; ODYNOPHAGIA; OSTEITIS; OTITIS MEDIA; PRIORITY JOURNAL; RETROPHARYNGEAL ABSCESS; SINGLE DRUG DOSE; TUBERCULOSIS; WILDLIFE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; ANIMALS, DOMESTIC; ANIMALS, WILD; BCG VACCINE; CATTLE; CHILD; CHILD, PRESCHOOL; FEMALE; GUINEA PIGS; HUMANS; INFANT; MALE; MICE; TUBERCULOSIS, BOVINE; TUBERCULOSIS, PULMONARY;

EID: 45649084323     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2007.11.010     Document Type: Article

References (121)

1. Calmette A. La vaccination preventive contre la tuberculose (1927), Mason et Cie, Paris
2. Anon. Report of the technical conference for the study of vaccination against tuberculosis by means of BCG. Pub League Natl Health 3 (1928) 1
3. Negre L. La vaccination antituberculeuse par le bacille de Calmette et Guérin (BCG). Biol Med 40 (1951)
4. Jouanguy E., Altare F., Lamhamedi S., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Eng Med 335 (1996) 1956-1961
5. Williams A., Hatch G., Clark S., et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 85 (2005) 28-29
6. Doherty T.M. Real world TB vaccines: clinical trials in TB-endemic regions. Vaccine 23 (2005) 2109-2114
7. Lotte A., Wasz-Hockert O., Poisson N., Dumitrescu N., Verron M., and Couvet E. BCG complications. Adv Tuberc Res 21 (1984) 107-193
8. Glover R.E., and Ritchie J.N. Field trials with BCG for the immunisation of calves against tuberculosis. Br Vet J 109 (1953) 411-427
9. Doyle T.M., and Stuart P. Vaccination of cattle with BCG. Br Vet J 114 (1958) 3-10
10. Stuart F.A., Mahmood K.H., Stanford J.L., and Pritchard D.G. Development of diagnostic tests, and vaccination against, tuberculosis in badgers. Mammal Rev 18 (1988) 74-75
11. Lesellier S., Palmer S., Dalley D.J., et al. The safety and immunogenicity of bacillus Calmette-Guerin (BCG) vaccine in European badgers (Meles meles). Vet Immunol Immunopathol 112 (2006) 24-37
12. Abolhassani M., Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun 68 (2000) 5657-5662
13. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., and Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 68 (2000) 1706-1709
14. Barclay W.R., Busey W.M., Dalgard D.W., et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacille Calmette-Guérin. Am Rev Respir Dis 107 (1973) 351-358
15. Guerin C. The history of BCG. In: Rosenthal S.R. (Ed). BCG vaccine: tuberculosis-cancer (1980), PSG Publishing Company, Littleton, MA 35-38
16. Behr M.A., and Small P.M. A historical and molecular phylogeny of BCG strains. Vaccine 17 (1999) 915-922
17. Oettinger T., Jorgensen M., Ladefoged A., Haslov K., and Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuberc Lung Dis 79 (1999) 243-250
18. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2 (2002) 86-92
19. Fomukong N.G., Dale J.W., Osborn T.W., and Grange J.M. Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. J Appl Bacteriol 72 (1992) 126-133
20. Behr M.A. Comparative genomics of BCG. Tuberculosis 81 (2001) 165-168
21. World Health Organisation. BCG vaccine. Wkly Epidemiol Rec 79 (2004) 27-38
22. Trunz B.B., Fine P., and Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367 (2006) 1173-1180
23. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
24. Sepulveda R.L., Parcha C., and Sorensen R.U. Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuberc Lung Dis 73 (1992) 372-377
25. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
26. Setia M.S., Steinmaus C., Ho C.S., and Rutherford G.W. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 6 (2006) 162-170
27. Lotte A., Wasz-Hockert O., Poisson N., et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 63 (1988) 47-59
28. Fitzgerald J.M. Management of adverse reactions to bacille Calmette-Guérin vaccine. Clin Infect Dis 31 (2000) S75-S76
29. Calmette A., Weill-Halle B., Saenz A., and Costil L. Démonstration expérimentale du passage des bacilles-vaccins BCG ŕ travers la muqueuse de l'intestin chez l'enfant et chez le singe. Bull Acad Med 110 (1933) 203-212
30. Gheorghiu M. Antituberculosis BCG vaccine: lessons from the past. In: Plotkin S.A., and Fantini B. (Eds). Vaccina, vaccination, vaccinology-Jenner, Pasteur and their successors (1996), Elsevier Science, Paris 87-94
31. Benévolo-de-Andrade T.C., Monteiro-Maia R., Cosgrove C., and Castello-Branco L.R. BCG Moreau Rio de Janeiro-an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz 100 (2005) 459-465
32. Wilson G.S. The hazards of immunization (1967), Athlone Press, London p. 66-73
33. Assis A. Tolerância do organismo adulto-alérgico ao BCG. O Hospital XXVIII (1945) 875-898
34. Cosgrove CA, Castello-Branco LRR, Hussell T, et al. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect Immun 2006; 2449-52.
35. Rosenthal S.R., McEnery J.T., and Raisys N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J Asthma Res 5 (1968) 309-323
36. Rosenthal S.R. BCG vaccine: tuberculosis-cancer (1980), PSG Publishing Company, Littleton, MA
37. de Souza G.R., Sant'Anna C.C., Lapa e Silva J.R., Mano D.B., and Bethlem N.M. Intradermal BCG vaccination complications-analysis of 51 cases. Tubercle 64 (1983) 23-27
38. Bolger T., O'Connell M., Menon A., and Butler K. Complications associated with the bacille Calmette-Guérin vaccination in Ireland. Arch Dis Child 91 (2006) 594-597
39. Teo S.S., Smeulders N., and Shingadia D.V. BCG vaccine-associated suppurative lymphadenitis. Vaccine 23 (2005) 2676-2679
40. Gorak-Stolinska P., Weir R.E., Floyd S., et al. Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 24 (2006) 5726-5733
41. Kroger L., Korppi M., Brander E., et al. Osteitis caused by bacille Calmette-Guérin vaccination: a retrospective analysis of 222 cases. J Infect Dis 172 (1995) 574-576
42. Bottiger M., Romanus V., deVerdier C., and Boman G. Osteitis and other complications caused by generalized BCG-itis. Acta Paediatr Scand 71 (1982) 471-478
43. Kroger L., Brander E., Korppi M., et al. Osteitis after newborn vaccination with three different bacillus Calmette-Guérin vaccines: twenty-nine years of experience. Pediatr Infect Dis J 13 (1994) 113-116
44. Vitkova E., Galliova J., Krepela K., and Kubin M. Adverse reactions to BCG. Cent Europ J Public Health 3 (1995) 138-141
45. Castro-Rodríguez J.A., González R., and Girardi G. Osteitis caused by bacille Calmette-Guérin vaccination: an emergent problem in Chile?. Int J Tuberc Lung Dis 1 (1997) 417-421
46. Brehmer W., Falkenberg N., Hussels H., Otto H.S., Preussler H., and Waldschmidt J. Regional suppurative lymphadenitis after BCG vaccination (author's transl). Dtsch Med Wochenschr 102 (1977) 1251-1255
47. Lehmann H.G., Engelhardt H., Freudenstein H., Hennessen W., and Widmark R.M. BCG vaccination of neonates, infants, school children and adolescents. Part I: dose finding studies with BCG strain 1331 Copenhagen. Dev Biol Stand 43 (1979) 127-132
48. Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes. A discussion document. World Health Organisation; 1999.
49. Jeena P.M., Chhagan M.K., Topley J., and Coovadia H.M. Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ 79 (2001) 337-343
50. Milstien J.B., and Gibson J.J. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 68 (1990) 93-108
51. Talbot E.A., Perkins M.D., Silva S.F., and Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis 24 (1997) 1139-1146
52. Liberek A., Korzon M., Bernatowska E., Kurenko-Deptuch M., and Rytlewska M. Vaccination-related Mycobacterium bovis BCG infection. Emerg Infect Dis 12 (2006) 860-862
53. Brodie T., Goodyear H., and Hackett S. Oral 7, cutaneous manifestations of disseminated BCG in a child with severe combined immunodeficiency. Br J Dermatol 156 6 (2007) 1405
54. Casanova J.L., Jouanguy E., Lamhamedi S., Blanche S., and Fischer A. Immunological conditions of children with BCG disseminated infection. Lancet 346 (1995) 581
55. Hesseling A.C., Rabie H., Marais B.J., et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 42 (2006) 559-561
56. World Health Organization. WHO report 2007. Global tuberculosis control: surveillance, planning, financing, Geneva; 2007.
57. Moss W.J., Clements C.J., and Halsey N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 81 (2003) 61-70
58. Hesseling A.C., Marais B.J., Gie R.P., et al. The risk of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 25 (2007) 14-18
59. Anonymous. Global Advisory Committee on vaccine safety. Wkly Epidemiol Rec 82 (2007) 18-24
60. Forum for Collaborative HIV Research. HIV-TB coinfection: meeting the challenge. 2007.
61. Armbruster C., Junker W., Vetter N., and Jaksch G. Disseminated bacille Calmette-Guérin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 162 (1990) 1216
62. Reynes J., Perez C., Lamaury I., Janbon F., and Bertrand A. Bacille Calmette-Guérin adenitis 30 years after immunization in a patient with AIDS. J Infect Dis 160 (1989) 727
63. Marsh B.J., von Reyn C.F., Edwards J., et al. The risks and benefits of childhood bacille Calmette-Guérin immunization among adults with AID. International MAC Study Groups. AIDS 11 (1997) 669-672
64. Griffith A.S. A study of the BCG strain of tubercle bacillus. Lancet 1 (1932) 303-8, 361-3
65. In: Irvine K.N. (Ed). The BCG vaccine (1934), Oxford University Press, London
66. Griffin J.F.T., Mackintosh C.G., Slobbe L., Thomson A.J., and Buchan G.S. Vaccine protocols to optimise the protective efficacy of BCG. Tuberc Lung Dis 79 (1999) 135-143
67. Buddle B.M., Keen D., Thomson A., et al. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res Vet Sci 59 (1995) 10-16
68. Aldwell F.E., Pfeffer A., De Lisle G.W., et al. Effectiveness of BCG vaccination in protecting possums against bovine tuberculosis. Res Vet Sci 58 (1995) 90-95
69. Abolhassani M., Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun 68 (2000) 5657-5662
70. Dannenberg A.M., Bishai W.R., Parrish N., et al. Efficacies of BCG and vole bacillus (Mycobacterium microti) vaccines in preventing clinically apparent pulmonary tuberculosis in rabbits: a preliminary report. Vaccine 19 (2000) 796-800
71. Cross M.L., Labes R.E., Griffin J.F., and Mackintosh C.G. Systemic but not intra-intestinal vaccination with BCG reduces the severity of tuberculosis infection in ferrets (Mustela furo). Int J Tuberc Lung Dis 4 (2000) 473-480
72. Lagranderie M., Ravisse P., Marchal G., et al. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuberc Lung Dis 74 (1993) 38-46
73. Lyadova I.V., Vordermeier H.M., Eruslanov E.B., Khaidukov S.V., Apt A.S., and Hewinson R.G. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs. Clin Exp Immunol 126 (2001) 274-279
74. Waters W.R., Palmer M.V., Whipple D.L., Slaughter R.E., and Jones S.L. Immune responses of white-tailed deer (Odocoileus virginianus) to Mycobacterium bovis BCG vaccination. J Wildl Dis 40 (2004) 66-78
75. Waters W.R., Palmer M.V., Olsen S.C., Sacco R.E., and Whipple D.L. Immune responses of elk to Mycobacterium bovis bacillus Calmette Guérin vaccination. Vaccine 21 (2003) 1518-1526
76. Wyman M., Rings M.D., Tarr M.J., and Alden C.L. Immunotherapy in equine sarcoid: a report of two cases. J Am Vet Med Assoc 171 (1977) 751-779
77. Orme I.M., and Collins F.M. Mouse model of tuberculosis. In: Bloom B.R. (Ed). Tuberculosis: pathogenesis, protection and control (1994), American Society for Microbiology, Washington, DC 113-134
78. McMurray D.N. Disease model: pulmonary tuberculosis. Trends Mol Med 7 (2001) 135-137
79. Martin C., Williams A., Hernandez-Pando R., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 (2006) 3408-3419
80. Francis J. Tuberculosis in animals and man. A study in comparative pathology (1958), Cassell, London
81. Ratcliffe H.L., and Palladino V.S. Tuberculosis induced by droplet nuclei infection: initial homogenous response of small mammals (rats, mice, guinea pigs and hamsters) to human and to bovine bacilli and the rate and pattern of tubercle development. J Exp Med 97 (1953) 61-68
82. McMurray D.N. A nonhuman primate model for preclinical testing of new tuberculosis vaccines. Clin Infect Dis 30 Suppl 3 (2000) S210-S212
83. Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 18 (2000) 1186-1195
84. Anon. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 79 (2004) 27-38
85. Moreira A.L., Tsenova L., Aman M.H., et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 70 (2002) 2100-2107
86. Smith D.W., Wiegeshaus E., Navalkar R., and Grover A.A. Host-parasite relationships in experimental airborne tuberculosis. I: preliminary studies in BCG-vaccinated and nonvaccinated animals. J Bacteriol 91 (1966) 718-724
87. Wiegeshaus E.H., McMurray D.N., Grover A.A., Harding G.E., and Smith D.W. Host-parasite relationships in experimental airborne tuberculosis. III: revelance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis 102 (1970) 422-429
88. Smith D.W., McMurray D.N., Wiegeshaus E.H., Grover A.A., and Harding G.E. Host-parasite relationships in experimental airborne tuberculosis. IV: early events in the course of infection in vaccinated and nonvaccinated guinea pigs. Am Rev Respir Dis 102 (1970) 937-948
89. Lagranderie M., Ravisse P., Marchal G., et al. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuberc Lung Dis 74 (1993) 38-46
90. Basaraba R.J., Izzo A.A., Brandt L., and Orme I.M. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 24 (2006) 280-286
91. Barclay W.R., Anacker R.L., Brehmer W., Leif W., and Ribi E. Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination. Infect Immun 2 (1970) 574-582
92. Langermans J.A., Andersen P., van Soolingen D., et al. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 98 (2001) 11497-11502
93. Buddle B.M., Wedlock D.N., and Denis M. Progress in the development of tuberculosis vaccines for cattle and wildlife. Vet Microbiol 112 (2006) 191-200
94. Skinner M.A., Wedlock D.N., and Buddle B.M. Vaccination of animals against Mycobacterium bovis. Rev Sci Tech (Int Off Epizootics) 20 (2001) 112-132
95. Corner L.A.L. The role of wild animal populations in the epidemiology of tuberculosis in domestic animals: how to assess the risk. Vet Microbiol 112 (2006) 303-312
96. Waddington F.G., and Ellwood D.C. An experiment to challenge the resistance to tuberculosis in BCG vaccinated cattle in Malawi. Br Vet J 128 (1972) 541-551
97. Ellwood D.C., and Waddington F.G. A second experiment to challenge the resistance to tuberculosis in BCG vaccinated cattle in Malawi. Br Vet J 128 (1972) 619-626
98. Berggren S.A. Field experiment with BCG vaccine in Malawi. Br Vet J 137 (1981) 88-94
99. Buddle B.M., Aldwell F.E., Skinner M.A., et al. Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis. Vaccine 23 (2005) 3581-3589
100. World Health Organisation (WHO)/Food and Agriculture Organisation (FAO). Report of WHO/FAO; 1951.
101. Buddle B.M., de Lisle G.W., Pfeffer A., and Aldwell F.E. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine 13 (1995) 1123-1130
102. Corner L.A., Outteridge P.M., Pearson W., and Lepper A.W. Immune mechanisms affecting bovine leucocytes during suppression of tuberculin skin sensitivity in cattle. Int Arch Allergy Appl Immunol 52 (1976) 3-14
103. Aldwell F.E., Keen D.L., Stent V.C., et al. Route of BCG administration in possums affects protection against bovine tuberculosis. N Z Vet J 43 (1995) 356-359
104. Buddle B.M., Aldwell F.E., Keen D.L., Parlane N.A., Yates G., and de Lisle G.W. Intraduodenal vaccination of brushtail possums with bacille Calmette-Guérin enhances immune responses and protection against Mycobacterium bovis infection. Int J Tuberc Lung Dis 1 (1997) 377-383
105. Corner L.A.L., Buddle B.M., Pfeiffer D.U., and Morris R.S. Aerosol vaccination of the brushtail possum (Trichosurus vulpecula) with bacille Calmette-Guérin: the duration of protection. Vet Microbiol 81 (2001) 181-191
106. Corner L.A.L., Buddle B.M., Pfeiffer D.U., and Morris R.S. Vaccination of the brushtail possum (Trichosurus vulpecula) against Mycobacterium bovis infection with bacille Calmette-Guérin: the response to multiple doses. Vet Microbiol 84 (2002) 327-336
107. Corner L.A.L., Norton S., Buddle B.M., and Morris R.S. The efficacy of bacille Calmette-Guérin vaccine in wild brushtail possums (Trichosurus vulpecula). Res Vet Sci 73 (2002) 145-152
108. Corner L.A., and Buddle B.M. Conjunctival vaccination of the brushtail possum (Trichosurus vulpecula) with bacille Calmette-Guérin. N Z Vet J 53 (2005) 133-136
109. Buddle B.M., Aldwell F.E., Keen D.L., Parlane N.A., Hamel K.L., and de Lisle G.W. Oral vaccination of brushtail possums with BCG: investigation into factors that may influence vaccine efficacy and determination of duration of protection. N Z Vet J 54 (2006) 224-230
110. Gormley E., and Collins J.D. The development of wildlife control strategies for eradication of tuberculosis in cattle in Ireland. Tuberc Lung Dis 80 (2000) 229-236
111. Mahmood KH. The immunological unresponsiveness of badgers to Mycobacteria. London: University of London; 1985.
112. Southey A., Sleeman D.P., Lloyd K., et al. Immunological responses of Eurasian badgers (Meles meles) vaccinated with Mycobacterium bovis BCG (bacillus Calmette-Guérin). Vet Immunol Immunopathol 79 (2001) 197-207
113. Brosch R., Gordon S.V., Garnier T., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104 (2007) 5596-5601
114. Chen J.M., Islam S.T., Huiping R., and Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 25 (2007) 8114-8122
115. Lagranderie M., Balazuc A.M., Deriaud E., Leclerc C.D., and Gheorghiu M. Comparison of immune responses of mice immunised with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 64 (1996) 1-9
116. Taylor J., Turner O.C., Basaraba R.J., Belise J.T., Huygen K., and Orme I.M. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 71 (2003) 2192-2198
117. Koch R. Fortsetzung der Mitteilungen uber ein Heilmittel gegen Tuberkulose. Dtsch Med Wochenschr 17 (1891) 101-102
118. Tala-Heikkila M.M., Tuominen J.E., and Tala E.O. Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 157 (1998) 1324-1327
119. Rahman M., Sekimoto M.D., Hira K., Koyama H., Imanaka Y., and Fukui T. Is bacillus Calmette-Guérin revaccination necessary for Japanese children?. Prev Med 35 (2002) 70-77
120. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348 (1996) 17-24
121. Tree J.A., Williams A., Clark S., Hall G., Marsh P.D., and Ivanyi J. Intranasal bacille Calmette-Guérin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin Exp Immunol 138 (2004) 405-409